Comparative efficacy and safety of secukinumab and ixekizumab in patients with active ankylosing spondylitis.

CONCLUSION: Secukinumab and ixekizumab were effective in active AS treatment, without the risk of SAEs. PMID: 32648054 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32648054?dopt=Abstract

Source: Zeitschrift fur Rheumatologie - July 8, 2020 Category: Rheumatology Authors: Lee YH, Song GG Tags: Z Rheumatol Source Type: research

More News: Ankylosing Spondylitis | Humira | Rheumatology